Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03887936 · ClinicalTrials.gov registry record · Phase 4
Testosterone Therapy and Bone Quality in Men With Diabetes and Hypogonadism
A Phase 4 study of Type 2 Diabetes Mellitus and Hypogonadism, sponsored by VA Office of Research and Development.
- Active
- Registry status
- Phase 4
- Development phase
- 92
- Enrollment target
- 1
- Study location
NCT03887936 is a Phase 4 study of Type 2 Diabetes Mellitus and Hypogonadism that is active but no longer recruiting, run by VA Office of Research and Development. The registered enrollment target is 92 participants, below the 2,748-participant average among 122 other Type 2 Diabetes Mellitus trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03887936, a Phase 4 study of Type 2 Diabetes Mellitus and Hypogonadism, is active but no longer recruiting, sponsored by VA Office of Research and Development.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 4
- Development phase
- 92 participants
- Enrollment target
- 1
- Study location
Study Summary
Low testosterone and diabetes mellitus are each associated with increased risk for fractures. Men with diabetes mellitus are commonly found to have low testosterone as well. Testosterone has been shown to improve the bone health of patients with low testosterone but has not been tested in patients who also have diabetes mellitus in addition to low testosterone. To date, there is no treatment that is specifically recommended for bone disease among patients with diabetes. This study will evaluate the effect of testosterone on the bone health of male Veterans who have both diabetes and low testosterone, both of which are highly prevalent in this subset of the population.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Testosterone gel 1.62%
Study Locations (1)
Texas
- Michael E. DeBakey VA Medical Center, Houston, TX - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 92 participants |
| Start Date | 2019-10-01 |
| Est. Completion | 2026-06-30 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03887936
The ClinicalTrials.gov registry entry for NCT03887936 describes a study currently listed as active not recruiting, categorized as Phase 4. The registered enrollment target is 92 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,748-participant average among 122 other Type 2 Diabetes Mellitus trials with a reported enrollment target (97% lower). The listed sponsor is VA Office of Research and Development, which has 1,668 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Type 2 Diabetes Mellitus appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT03887936 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT03887936 about?
NCT03887936 is a clinical study titled "Testosterone Therapy and Bone Quality in Men With Diabetes and Hypogonadism". Low testosterone and diabetes mellitus are each associated with increased risk for fractures. Men with diabetes mellitus are commonly found to have low testosterone as well. Testosterone has been shown to improve the bone health of patients with low testosterone but has not been tested in patients w...
What is the current status of trial NCT03887936?
This trial is currently active not recruiting. It is a Phase 4 study. The enrollment target is 92 participants. The study started on 2019-10-01. Estimated completion is 2026-06-30.
What conditions does trial NCT03887936 study?
This clinical trial studies the following conditions: Type 2 Diabetes Mellitus, Hypogonadism.
What interventions are being tested in trial NCT03887936?
The interventions under investigation include: Placebo (DRUG), Testosterone gel 1.62% (DRUG).
Who is sponsoring clinical trial NCT03887936?
This trial is sponsored by VA Office of Research and Development, which has 1,668 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03887936 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Type 2 Diabetes Mellitus
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Does Pioglitazone Increase the Production of 15-EPI-Lipoxin A4?
COMPLETED · Phase 4
-
Adding Liraglutide to High Dose Insulin: Breaking the Cycle
COMPLETED · Phase 4
-
Vascular Effects of Rosiglitazone Versus Glyburide in Type 2 Diabetic Patients
COMPLETED · Phase 4
-
Insulin Resistance and Central Nervous System (CNS) Function in Type 2 Diabetes
COMPLETED · Phase 4
-
Effect Of Exenatide Treatment on Liver Fat Content in Patients With Diabetes
COMPLETED · Phase 4
-
Suvorexant on Sleep Disturbance in Patients With Chronic Insomnia and Suboptimally Controlled Type 2 Diabetes
COMPLETED · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.